Menopause International > Volume 14, Number 3 > Pp. 136-137

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Pitkin, J. Search for Related Content PubMed PubMed Citation Social Bookmarking                      What's this?

British Menopause Society Council Consensus Statement

Urogenital atrophy

Joan Pitkin, Margaret Rees  on behalf of the British Menopause Society Council

Correspondence: Margaret Rees, MA DPhil FRCOG, Reader in Reproductive Medicine, University of Oxford, Visiting Professor, Faculty of Medicine, University of Glasgow, Honorary Consultant in Medical Gynaecology, Level 4, Women's Centre, John Radcliffe Hospital, Oxford OX3 9DU, UK. Email: margaret.rees{at}obs-gyn.ox.ac.uk
The British Menopause Society Council aims to aid health professionals to inform and advise women about postreproductive health. This guidance refers to the long-term condition of urogenital atrophy. Treatment choice should be based on up to date information and targeted to individual women's needs. Non-estrogen and estrogen-based treatments are discussed.

Key Words: Ageing • bioadhesive moisturizers • postreproductive health • urogenital atrophy • vaginal estrogen

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?